Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02907177 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
A Phase 3 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT02907177 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 136 participants.
The verdict
NCT02907177, a Phase 3 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
Interventions
- OTHER Placebo
- DRUG Ponesimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2020-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02907177
The ClinicalTrials.gov registry entry for NCT02907177 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02907177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02907177 about?
NCT02907177 is a clinical study titled "Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)". This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
What is the current status of trial NCT02907177?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2017-03-30. Estimated completion is 2020-03-26.
What interventions are being tested in trial NCT02907177?
The interventions under investigation include: Placebo (OTHER), Ponesimod (DRUG).
Who is sponsoring clinical trial NCT02907177?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.